Microbiological rationale for the utilisation of prulifloxacin, a new fluoroquinolone, in the eradication of serious infections caused by Pseudomonas aeruginosa

• Published in: International journal of antimicrobial agents Vol. 26; no. 5; pp. 366 - 372
• Main Authors: Roveta, Simona, Schito, Anna Maria, Marchese, Anna, Schito, Gian Carlo
• Format: Journal Article
• Language: English
• Published: London Elsevier B.V 01.11.2005; Amsterdam Elsevier; New York, NY
• Subjects: Anti-Bacterial Agents - administration & dosage; Anti-Bacterial Agents - therapeutic use; Antibiotics. Antiinfectious agents. Antiparasitic agents; Aza Compounds - therapeutic use; Biological and medical sciences; Ciprofloxacin - therapeutic use; Cystic fibrosis; Cystic Fibrosis - complications; Cystic Fibrosis - microbiology; Dioxolanes - administration & dosage; Dioxolanes - therapeutic use; Drug Resistance, Bacterial; Errors of metabolism; Fluoroquinolones - administration & dosage; Fluoroquinolones - therapeutic use; Humans; In Vitro Techniques; Levofloxacin; Medical sciences; Metabolic diseases; Microbial Sensitivity Tests; Miscellaneous hereditary metabolic disorders; Mutant prevention concentration; Ofloxacin - therapeutic use; Opportunistic Infections - drug therapy; Opportunistic Infections - etiology; Opportunistic Infections - microbiology; Pharmacology. Drug treatments; Piperazines - administration & dosage; Piperazines - therapeutic use; Pseudomonas aeruginosa - drug effects; Pseudomonas aeruginosa - isolation & purification; Pseudomonas Infections - drug therapy; Pseudomonas Infections - etiology; Pseudomonas Infections - microbiology; Quinolines - therapeutic use; Quinolones - administration & dosage; Quinolones - therapeutic use; Susceptibility tests; Time–kill; Susceptibility tests; Cystic fibrosis; Time–kill; Mutant prevention concentration; Pseudomonadales; Eradication; Prevention; Fluoroquinolone derivatives; Isomerases; Bacteria; Pseudomonadaceae; Pseudomonas aeruginosa; Quinolone derivatives; Pancreatic disease; DNA topoisomerase (ATP-hydrolysing); Time-kill; Respiratory disease; Enzyme; Enzyme inhibitor; Metabolic diseases; Prulifloxacin; Concentration; Genetic disease; Infection; Sensitivity; Digestive diseases; Mutation; Antibacterial agent
• ISSN: 0924-8579; 1872-7913
• DOI: 10.1016/j.ijantimicag.2005.07.015

Minimal inhibitory concentrations (MICs) of prulifloxacin were evaluated in comparison with ciprofloxacin, levofloxacin and moxifloxacin against a large collection ( N = 300) of Pseudomonas aeruginosa strains characterised according to the CLSI/NCCLS microdilution method. Additional in vitro tests (time–kill curves and mutant prevention concentration (MPC) determinations) were carried out. Assuming a susceptibility breakpoint for prulifloxacin identical to that of ciprofloxacin, the new fluoroquinolone emerged as the most potent antibiotic (72% of susceptible strains versus 65%, 61% and 23% for ciprofloxacin, levofloxacin and moxifloxacin, respectively). Time–kill tests at 4× MIC confirmed the pronounced bactericidal potency of the drug against P. aeruginosa. Amongst the members of the fluoroquinolone class assessed, prulifloxacin produced the lowest MPC values (≤4 mg/L). Our in vitro results indicate that prulifloxacin represents the most powerful antipseudomonal drug available today.